本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议的基本情况 1、股东会届次：2025年第四次临时股东会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易 所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号—创业 板上市公司规范运作》等法律、行政法规、部门规章、规范性文件及《公司章 程》的有关规定。 证券代码：301087 证券简称：可孚医疗 公告编号：2025-080 可孚医疗科技股份有限公司 关于召开 2025 年第四次临时股东会的通知 4、会议时间： （1）现场会议时间：2025年11月14日（星期五）14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025年11月14日9:15-9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联 网投票系统投票的具体时间为2025年11月14日9:15至15:00的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025年11月6日（星期四） 7、出席对象： ...

证券代码：301087 证券简称：可孚医疗 公告编号：2025-076 可孚医疗科技股份有限公司 第二届董事会第十九次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 可孚医疗科技股份有限公司（以下简称"公司"）第二届董事会第十九次会 议于 2025 年 10 月 25 日以电子邮件的方式发出会议通知，会议于 2025 年 10 月 29 日上午 8:30 以通讯方式召开。会议应出席董事 7 名，实际出席董事 7 人，公 司高级管理人员列席了会议。本次会议由董事长张敏先生主持。会议的召集和召 开符合《中华人民共和国公司法》等法律法规和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事对本次会议需审议的议案进行了充分讨论，审议通过了以下议案： 1、审议通过了《关于公司<2025 年第三季度报告>的议案》 公司 2025 年第三季度报告全文及其摘要遵循相关法律法规及规范性文件要 求编制，报告内容真实、准确、完整地反映了公司 2025 年第三季度的经营情况， 不存在任何虚假记载、误导性陈述或者重大遗漏。 本议案已经公司董事会审计 ...

Financial Performance - The company's revenue for Q3 2025 reached ¥902,027,920.61, representing a year-over-year increase of 30.72%[5] - Net profit attributable to shareholders was ¥92,829,784.04, up 38.68% compared to the same period last year[5] - The net profit excluding non-recurring gains and losses increased by 62.68% to ¥85,802,669.67[5] - The basic earnings per share for the quarter was ¥0.46, reflecting a growth of 39.39% year-over-year[5] - Total revenue for the third quarter reached ¥2,397,791,920.73, an increase of 6.63% compared to ¥2,248,651,846.83 in the previous year[28] - The net profit for the current period is CNY 259,507,645.73, an increase from CNY 251,937,817.59 in the previous period, representing a growth of approximately 3.5%[29] - The basic earnings per share for the current period is CNY 1.28, up from CNY 1.24 in the previous period, which is an increase of about 3.2%[30] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥6,540,292,345.50, a 1.83% increase from the end of the previous year[5] - Current liabilities rose to ¥1,637,988,672.10, compared to ¥1,361,721,170.48, representing an increase of 20.29%[26] - The company’s total liabilities increased significantly, with other current liabilities rising by 6437.58% to ¥10,703,673.10, mainly due to an increase in endorsed but not yet due non-A rated notes[10] - The total equity attributable to shareholders decreased to ¥4,713,657,384.44 from ¥4,796,596,352.25, a decline of 1.73%[27] Cash Flow - The company reported a net cash flow from operating activities of ¥589,991,388.19, which is a 35.36% increase compared to the previous period[13] - The cash flow from operating activities net amount is CNY 589,991,388.19, up from CNY 435,875,379.93, indicating a significant increase of approximately 35.4%[31] - The cash and cash equivalents balance increased to ¥1,297,129,950.07 from ¥1,278,679,967.98, reflecting a growth of 1.04%[25] - The cash and cash equivalents at the end of the period amount to CNY 1,211,867,558.21, down from CNY 1,682,965,410.24, indicating a decrease of approximately 28.0%[32] - The net cash flow from investing activities is CNY -166,212,273.98, slightly worse than CNY -157,365,720.23 in the previous period, showing a decline of about 5.4%[32] - The company’s total liabilities increased, with cash outflow for financing activities amounting to CNY 1,486,487,292.43, compared to CNY 1,028,640,120.66 in the previous period, reflecting an increase of approximately 44.4%[32] Investments and Shareholder Information - The company’s long-term equity investments increased by 48.99% to ¥91,522,254.96, attributed to new equity investments made during the period[10] - The largest shareholder, a domestic non-state legal entity, holds 40.73% of shares, totaling 85,079,923 shares[15] - The top 10 shareholders include several investment partnerships, with the largest holding being 85,079,923 shares[16] - The company has a share buyback account holding 5,699,731 shares, representing 2.73% of total equity[16] - The total number of restricted shares at the end of the period is 97,498 shares after adjustments[19] - The company has no preferred shareholders or changes in preferred shareholder status[17] Future Plans and Strategies - The company plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance global strategy and brand recognition[20] - A cash dividend of 6 RMB per 10 shares will be distributed, totaling 121,918,361.40 RMB (including tax) for the 2025 semi-annual profit distribution[21] - The company plans to expand its market presence and invest in new product development, focusing on innovative technologies[26] Operating Costs and Expenses - Total operating costs amounted to ¥2,140,937,840.58, up from ¥1,972,854,349.55, reflecting a year-over-year increase of 8.52%[28] - Research and development expenses were ¥61,091,966.84, a decrease of 12.5% from ¥69,408,244.31 in the previous year[28]

可孚医疗科技股份有限公司 会计师事务所选聘制度 第一章 总则 第一条 为进一步规范可孚医疗科技股份有限公司（以下简称"公司"）选 聘（含续聘、改聘，下同）会计师事务所的行为，切实维护股东利益，提高审 计工作和财务信息的质量，依据《中华人民共和国公司法》《国有企业、上市 公司选聘会计师事务所管理办法》等法律法规、规范性文件和《可孚医疗科技 股份有限公司章程》（以下简称《公司章程》）等有关规定，结合公司实际情 况，制定本制度。 第二条 本制度所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告发表审计意见、出具审计报告的行为。公司 聘任会计师事务所从事除财务会计报告审计之外的其他法定审计业务的，可以 比照本制度执行。 第三条 公司选聘会计师事务所应当经董事会审计委员会（以下简称"审 计委员会"）审议同意后，提交董事会和股东会审议。 第二章 选聘会计师事务所的执业质量要求 第四条 公司选聘的会计师事务所应当具备下列条件： （一）具有独立的主体资格，具备国家行业主管部门和中国证监会规定的 开展证券期货相关业务所需的执业资格； （二）具有固定的工作场所、健全的组织机构和完善的内部管理和控 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has announced additional requirements for the overseas issuance and listing of Kefu Medical, emphasizing the need for clarification on the company's domestic subsidiaries and their qualifications for conducting certain business activities [1] Group 1: Company Overview - Kefu Medical is recognized as one of the largest home medical device companies in China, ranking second among all home medical device enterprises based on sales in 2024 according to Frost & Sullivan [1] - As of June 30, 2025, Kefu Medical operates 738 self-owned stores in China, with 689 of these being "Jianer Hearing" service centers, covering over 135 cities in the country [1] Group 2: Regulatory Requirements - The CSRC requires Kefu Medical to further explain whether its domestic subsidiaries comply with the regulations regarding overseas issuance of securities [1] - The company must provide details on its subsidiaries' business scope, particularly in "advertising publishing" and "advertising design and agency," including whether they have obtained the necessary qualifications and licenses [1] - Additionally, Kefu Medical is asked to clarify its subsidiaries' operations in "internet information services" and other business areas, ensuring compliance with relevant regulations [1]

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has requested additional information from Kefu Medical regarding its overseas listing application, focusing on compliance with regulations and operational details of its subsidiaries [1][2]. Group 1: Regulatory Compliance - CSRC requires Kefu Medical to clarify whether its domestic subsidiaries fall under the prohibitions outlined in the "Interim Measures for the Administration of Overseas Issuance and Listing of Domestic Enterprises" [1] - The company must provide details on its subsidiaries' business scope, particularly in advertising and internet information services, and confirm whether they have obtained the necessary licenses [1]. Group 2: Company Overview - Kefu Medical is one of the largest home medical device companies in China, ranking second in sales among all home medical device enterprises according to Frost & Sullivan [2]. - The company has expanded its global presence, covering over 60 countries and regions across Asia, Africa, Europe, and America, attracting a growing loyal customer base [2]. - As of June 30, 2025, Kefu Medical operates 738 self-owned stores in China, with 689 being "Jianer Hearing" service centers, providing professional hearing testing services and various quality hearing aid products [2].

Core Insights - The China Securities Regulatory Commission (CSRC) has requested additional information from Kefu Medical regarding its overseas listing application, specifically concerning its domestic subsidiaries and compliance with regulations [1] - Kefu Medical is one of the largest home medical device companies in China, ranking second in sales among all home medical device enterprises according to Frost & Sullivan [2] - The company has expanded its global presence, covering over 60 countries and regions across Asia, Africa, Europe, and America, attracting a growing loyal customer base [2] Group 1 - The CSRC requires Kefu Medical to clarify whether its domestic subsidiaries fall under the prohibitions outlined in the "Interim Measures for the Administration of Overseas Issuance and Listing of Domestic Enterprises" [1] - Kefu Medical operates 738 self-owned stores in China, with 689 being "Jianer Hearing" service centers, covering over 135 cities [2] - The "Jianer Hearing" service centers provide professional hearing testing services and supply various high-quality hearing aid products, including Kefu's own brand [2] Group 2 - The CSRC has asked Kefu Medical to provide details on its subsidiaries' business scope, including advertising services, and whether they have obtained the necessary licenses [1] - Kefu Medical's "Jianer Hearing" ranks among the top three in the industry based on the number of hearing aid fitting centers in China as of the end of 2024 [2] - The company is also required to explain its compliance with foreign investment restrictions as outlined in the "Negative List for Foreign Investment Access (2024 Edition)" [1]

Core Viewpoint - A-share listed companies are increasingly implementing mid-term dividends, with a total of nearly 660 billion yuan distributed, approaching last year's total mid-term dividends [1][2] Group 1: Company Dividends - China Merchants Industry Holdings (中远海控) announced a cash dividend of 0.56 yuan per share, totaling nearly 8.7 billion yuan [1] - Changsha Bank plans to distribute over 800 million yuan in cash dividends, the highest among listed companies in Hunan [1][2] - Foxconn Industrial Internet and Beijing Yanjing Beer announced their first mid-term dividends of 6.551 billion yuan and 282 million yuan, respectively [2] Group 2: Company Performance - China Merchants Industry Holdings reported earnings per share of 1.12 yuan and a net profit of approximately 1.75 billion yuan, with a year-on-year growth rate of 3.95% [1] - Kefu Medical reported earnings per share of 0.82 yuan and a net profit of approximately 167 million yuan, with a year-on-year decline of 9.51% [3] - Changsha Bank reported earnings per share of 1.08 yuan and a net profit of approximately 4.33 billion yuan, with a year-on-year growth rate of 5.05% [3] Group 3: Industry Trends - Over 850 A-share listed companies have announced or implemented mid-term dividend plans, with over 442 companies having a total market value exceeding 10 billion yuan, accounting for over 50% of the total [2] - The trend of companies practicing multiple dividends a year is expected to attract long-term investment and enhance market resilience [3]

Market Overview - On October 22, the medical device sector declined by 0.71%, with Kewei Medical leading the drop [1] - The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1] Top Performers - Shengxiang Biological (688289) saw a closing price of 22.02, with an increase of 8.31% and a trading volume of 254,100 shares, totaling 550 million yuan [1] - Meihua Medical (301363) closed at 23.83, up 6.53%, with a trading volume of 128,000 shares, amounting to 300 million yuan [1] - Lideman (300289) closed at 8.19, increasing by 6.36%, with a trading volume of 529,400 shares, totaling 433 million yuan [1] Underperformers - Kewei Medical (301087) closed at 40.63, down 4.78%, with a trading volume of 27,100 shares, totaling 112 million yuan [2] - Lepu Medical (300003) closed at 17.35, down 4.41%, with a trading volume of 330,000 shares, totaling 580 million yuan [2] - Ruimaite (301367) closed at 87.18, down 3.48%, with a trading volume of 15,100 shares, totaling 133 million yuan [2] Capital Flow - The medical device sector experienced a net outflow of 332 million yuan from institutional investors, while retail investors saw a net inflow of 261 million yuan [2][3] - The top net inflows from retail investors included Lideman (300289) with a net outflow of 80.35 million yuan, and Shengxiang Biological (688289) with a net outflow of 17.66 million yuan [3]

Core Insights - The cervical traction device market in China is projected to grow from 1.414 billion yuan in 2016 to 4.746 billion yuan in 2024, with a compound annual growth rate (CAGR) of 16.34% [1][10] - The increasing prevalence of cervical spondylosis among younger populations, particularly those under 30, has created a substantial user base for cervical traction devices [7][10] - Non-invasive conservative treatment options, such as cervical traction devices, are becoming the preferred choice due to their safety and convenience [1][10] Industry Overview - Cervical spondylosis is a degenerative condition affecting the cervical spine, with over 200 million patients in China, where more than 40% are under 30 years old [7][10] - The treatment methods for cervical spondylosis include non-surgical and surgical options, with traction being a primary non-surgical method to alleviate symptoms [3][7] - The cervical traction device market is supported by advancements in medical technology, leading to the development of smart and home-use devices that lower usage barriers [1][10] Market Dynamics - The cervical traction device industry is influenced by government policies promoting home medical devices and improving industry standards, creating a favorable environment for market expansion [1][10] - The medical device industry in China is experiencing rapid growth, with the overall market size expected to increase from 370 billion yuan in 2016 to 1.13 trillion yuan in 2024, reflecting a CAGR of 14.98% [10] Competitive Landscape - The cervical traction device market features a diverse competitive landscape, with established medical device companies and emerging tech firms participating [11] - Key players in the market include Yuyue Medical, Kefu Medical, and other brands that leverage innovation and user experience to capture the younger demographic [11] - The competition is shifting from price-based to technology development, user experience, and brand credibility, driving the industry towards standardization and quality improvement [11] Development Trends - The industry is moving towards smart devices that integrate high-precision sensors and algorithms for personalized treatment [13][14] - There is a growing trend towards personalized solutions based on individual physiological characteristics and specific conditions [14] - The demand for portable devices is increasing, with innovations in lightweight materials and compact designs enhancing user convenience [15]